LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company building the first nationwide, commission-only pharmaceutical sales force, announced today the signing of a manufacturing and supply agreement with Mikart, Inc., pursuant to which Auriga will have the exclusive rights to market and sell a new product indicated for the relief of mild to moderately severe pain in the United States. The new product combines the effects of a centrally acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen, in a unique strength previously not available.
